The Latest Breaking News from FDA

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

The pharmaceutical industry is experiencing rapid growth thanks to healthcare demand, regulatory initiatives, and technological adoption in drug discovery and development. Hence, it could be wise to invest in pharma stocks Ipsen (IPSEY), Bristol-Myers (BMY), and Taro Pharmaceutical (TARO) to drive your bottom line. These stocks are rated A (Strong…

The research the FDA relies upon to claim banning menthol cigarettes would improve public health is not aligned with the agency's approach to tobacco regulation.

ShivamoggaHassan Deputy Commissioner suspends official for forwarding political message on WhatsApp, violating model code of conduct.

Exclusive-Synchron's FDA-approved brain implant trial showcases advancements in brain-computer interface technology, shaping the future of neurotechnology.

The government still blames the private sector despite its own role in creating, exacerbating, and prolonging the shortage.

FDA warns against selling ZYN nicotine pouches to minors, emphasizing risks of nicotine addiction and underage tobacco use.

Amylyx Pharmaceuticals withdraws Relyvrio drug for ALS due to lack of efficacy, leading to layoffs and disappointment in ALS community.

A human case of avian influenza in Texas this week has prompted Congress to gather information about risks to public health and agriculture.